Pfizer Inc.

Industry

  • Pharmaceuticals
    • Generic Drugs
  • Digital Health
    • Disease Management

Other Names/Subsidiaries

  • Agouron Pharmaceuticals
  • Alpharma Pharmaceuticals
  • American Home Products
  • Amplyx Pharmaceuticals
  • Anacor Pharmaceuticals
  • Arena Pharmaceuticals
  • Array BioPharma
  • Arixa Pharmaceuticals
  • Bamboo Therapeutics
  • Biohaven Pharmaceutical Holding
  • BioRexis Pharmaceutical
  • Bioren
  • Coley Pharmaceutical Group
  • CovX Pharmaceuticals
  • C.P. Pharmaceuticals International
  • Desitin
  • Encysive Pharmaceuticals
  • Esperion Therapeutics
  • Excaliard Pharmaceuticals
  • Ferrosan Consumer Health
  • FoldRx Pharmaceuticals
  • GD Searle
  • Greenstone
  • Hisun-Pfizer Pharmaceuticals
  • Hospira
  • Icagen
  • Idun Pharmaceuticals
  • InnoPharma
  • Javelin Pharmaceuticals
  • Jones Pharma
  • King Pharmaceuticals
  • Lederle Laboratories
  • Lederle-Praxis Biologics
  • Mayne Pharma
  • Medivation
  • Meridian Medical Technologies
  • Neusentis
  • NextWave Pharmaceuticals
  • Parke-Davis
  • Pharmacia
  • Pharmacia and Upjohn
  • PHT Pharma
  • Powdermed
  • Redvax
  • ReViral
  • Rinat Neuroscience
  • Seagen
  • Serenex
  • Strato Medical
  • SUGEN
  • Synbiotics
  • Texas Biotechnology Corporation
  • Thiakis
  • Trillium Therapeutics
  • Treerly Health
  • Vicuron Pharmaceuticals
  • ViiV Healthcare
  • Warner-Lambert
  • Wyeth
  • Wyeth-Ayerst Laboratories
  • and BIND Therapeutics.
See more in Biomedtracker

Latest on Pfizer Inc.

Scrip

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

 
• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis Inks Four-Year Proteome Resear

Pink Sheet

Merck’s Clesrovimab Vote Reflects New ACIP Members’ Skepticism

 
• By Sue Sutter

A US Centers for Disease Control and Prevention panel’s divided endorsement of Merck & Co .’s Enflonsia (clesrovimab-cfor) for prevention of respiratory syncytial virus in infants suggests that p

Scrip

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

Pfizer stands to expand the addressable market for its hemophilia A and B drug Hympavzi (marstacimab-hncq) with Phase III data showing it is effective in patients with clotting factor inhibitors along

Scrip

Kymera Inks CDK2 Deal With Gilead

 
• By Alaric DeArment

Who: Kymera Therapeutics with Gilead Sciences What: On June 25, Kymera announced a deal with Gilead for molecular glue degraders targeting CDK2. Why: While potent anti-cancer drugs, traditional C